{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:41:02Z","timestamp":1787582462826,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.maturitas.2026.108896","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:50:14Z","timestamp":1772095814000},"page":"108896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Assessment of medication-related risks for mortality prediction in Alzheimer's disease"],"prefix":"10.1016","volume":"208","author":[{"given":"Th\u00e9odore","family":"Decaix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dumurgier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Bouaziz-Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Cognat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mouton-Liger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Hugon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Vrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Lilamand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2026.108896_bb0005","article-title":"Deprescribing in older adults with polypharmacy","volume":"385","author":"Hung","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2026.108896_bb0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/2042098616670798","article-title":"Polypharmacy and inappropriate medication use in patients with dementia: an underresearched problem","volume":"8","author":"Parsons","year":"2017","journal-title":"Ther. Adv. Drug. Saf."},{"key":"10.1016\/j.maturitas.2026.108896_bb0015","article-title":"Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia","volume":"8","author":"Taylor-Rowan","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.maturitas.2026.108896_bb0020","article-title":"Association between anticholinergic burden and dementia in UK biobank","volume":"8","author":"Mur","year":"2022","journal-title":"Alzheimers Dement. (N Y)."},{"key":"10.1016\/j.maturitas.2026.108896_bb0025","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/0091270006292126","article-title":"The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity","volume":"46","author":"Carnahan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.maturitas.2026.108896_bb0030","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","article-title":"The anticholinergic risk scale and anticholinergic adverse effects in older persons","volume":"168","author":"Rudolph","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.maturitas.2026.108896_bb0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: a review and practical application","volume":"4","author":"Boustani","year":"2008","journal-title":"Aging Health"},{"key":"10.1016\/j.maturitas.2026.108896_bb0040","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s41999-023-00777-y","article-title":"STOPP\/START criteria for potentially inappropriate prescribing in older people: version 3","volume":"14","author":"O'Mahony","year":"2023","journal-title":"Eur. Geriatr. Med."},{"key":"10.1016\/j.maturitas.2026.108896_bb0045","first-page":"2052","article-title":"By the 2023 American Geriatrics Society Beers Criteria\u00ae update expert panel, American Geriatrics Society 2023 updated AGS beers criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.maturitas.2026.108896_bb0050","article-title":"Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment","volume":"12","author":"Taylor-Rowan","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.maturitas.2026.108896_bb0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JAD-170265","article-title":"Potentially inappropriate medication, anticholinergic burden, and mortality in people attending memory clinics","volume":"60","author":"Cross","year":"2017","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"10.1016\/j.maturitas.2026.108896_bb0060","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00228-022-03410-2","article-title":"Potentially inappropriate medication use and mortality in patients with cognitive impairment","volume":"78","author":"Buckley","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.maturitas.2026.108896_bb0065","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer disease as a clinical-biological construct-an international working group recommendation","volume":"81","author":"Dubois","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.maturitas.2026.108896_bb0070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00415-013-7160-3","article-title":"Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study","volume":"261","author":"Mouton-Liger","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.maturitas.2026.108896_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100009","article-title":"Usefulness of cerebrospinal fluid Alzheimer\u2019s disease biomarkers in older patients: evidence from a national multicenter prospective study","volume":"12","author":"Decaix","year":"2025","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.maturitas.2026.108896_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13195-023-01220-x","article-title":"Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders","volume":"15","author":"R\u00e9gy","year":"2023","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.maturitas.2026.108896_bb0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13195-019-0481-4","article-title":"CSF level of \u03b2-amyloid peptide predicts mortality in Alzheimer\u2019s disease","volume":"11","author":"Boumenir","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.maturitas.2026.108896_bb0090","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13195-025-01814-7","article-title":"Dual risk of anticholinergic burden and CSF alzheimer\u2019s biomarkers in older patients: a mortality follow-up study from daily medical practice","volume":"17","author":"Decaix","year":"2025","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.maturitas.2026.108896_bb0095","doi-asserted-by":"crossref","unstructured":"C.R. Jr. Jack, D.A. Bennett, K. Blennow, M.C. Carrillo, B. Dunn, S.B. Haeberlein, D.M. Holtzman, W. Jagust, F. Jessen, J. Karlawish, E. Liu, J.L. Molinuevo, T. Montine, C. Phelps, K.P. Rankin, C.C. Rowe, P. Scheltens, E. Siemers, H.M. Snyder, R. Sperling; Contributors, NIA-AA research framework: toward a biological definition of Alzheimer's disease, Alzheimers Dement. 14 (2018) 535\u2013562. doi:https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"10.1016\/j.maturitas.2026.108896_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/ncp.70090","article-title":"From pills to plate: anticholinergic burden and malnutrition in older adults across three nutrition assessment tools: a cross-sectional study","author":"Simsek","year":"2026","journal-title":"Nutr. Clin. Pract."},{"key":"10.1016\/j.maturitas.2026.108896_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2021.06.004","article-title":"Anticholinergics and clinical outcomes amongst people with pre-existing dementia: a systematic review","volume":"151","author":"Wang","year":"2021","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2026.108896_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083224","article-title":"Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer\u2019s disease: a national population cohort study","volume":"9","author":"Gnjidic","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.maturitas.2026.108896_bb0115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bcpt.13184","article-title":"Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study","volume":"124","author":"Ah","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.maturitas.2026.108896_bb0120","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/JAD-180353","article-title":"Anticholinergic burden and risk of stroke and death in people with different types of dementia","volume":"65","author":"Tan","year":"2018","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"10.1016\/j.maturitas.2026.108896_bb0125","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/gps.5330","article-title":"The anticholinergic effect on cognition (AEC) scale-associations with mortality, hospitalisation and cognitive decline following dementia diagnosis","volume":"35","author":"Bishara","year":"2020","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.maturitas.2026.108896_bb0130","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1080\/13607863.2020.1830028","article-title":"Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland","volume":"25","author":"McMichael","year":"2021","journal-title":"Aging Ment. Health."},{"key":"10.1016\/j.maturitas.2026.108896_bb0135","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/phar.2652","article-title":"Anticholinergic medication burden and cognitive function in participants of the ASPREE study","volume":"42","author":"Broder","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.maturitas.2026.108896_bb0140","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer's disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.maturitas.2026.108896_bb0145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00401-023-02616-7","article-title":"Inflammation and the pathological progression of Alzheimer's disease are associated with low circulating choline levels","volume":"146","author":"Judd","year":"2023","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.maturitas.2026.108896_bb0150","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s11357-021-00497-w","article-title":"Inverse association between the anticholinergic burden and hippocampus volume in a population-based cohort across the entire adult age range","volume":"44","author":"Kilimann","year":"2022","journal-title":"Geroscience"},{"key":"10.1016\/j.maturitas.2026.108896_bb0155","doi-asserted-by":"crossref","first-page":"e2313","DOI":"10.1212\/WNL.0000000000201161","article-title":"Effect of cholinesterase inhibitors on mortality in patients with dementia: a systematic review of randomized and nonrandomized trials","volume":"99","author":"Truong","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.maturitas.2026.108896_bb0160","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1111\/jgs.13647","article-title":"Health, aging and body composition study, concordance between anticholinergic burden scales","volume":"63","author":"Naples","year":"2015","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.maturitas.2026.108896_bb0165","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/gps.4844","article-title":"Registry of dementia of Girona study group (ReDeGi study group), measuring anticholinergic exposure in patients with dementia: a comparative study of nine anticholinergic risk scales","volume":"33","author":"Turr\u00f3-Garriga","year":"2018","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.maturitas.2026.108896_bb0170","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.sapharm.2015.11.002","article-title":"Development, validation and evaluation of an electronic pharmacological tool: the drug burden index calculator\u00a9","volume":"12","author":"Kouladjian","year":"2016","journal-title":"Res. Social Adm. Pharm."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T21:25:39Z","timestamp":1779485139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512226000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"alternative-id":["S0378512226000733"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108896","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of medication-related risks for mortality prediction in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108896"}}